Kolmar Korea Reports Strong Q1 2026: Sales KRW 728B, Operating Profit KRW 78.9B

Q1 2026 consolidated sales KRW 728.0B, operating profit KRW 78.9B, net profit KRW 60.0B (controlling KRW 45.2B).
Cosmetics ODM sales KRW 343.0B (47%), pharma (K-Cab etc.) KRW 239.1B (33%), packaging KRW 62.4B (9%), H&B KRW 18.6B (3%).
K-Cab global expansion: under review in US/China, launched in Latin America and SE Asia.
Pipeline: JAK1 inhibitor phase 2, GLP-1 obesity drug phase 3, denosumab biosimilar approved.
Debt ratio 116.4% (vs 107.4% year-end), net debt ratio 59.0% (vs 51.9%).
Dividend policy: payout ratio ≥10%, stable dividends (shareholder return).
New subsidiaries Kolmar Mask and Kolmar UX consolidated; Yonwoo full integration synergy.